Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
The AI response partially aligns with the FDA label. It correctly acknowledges some drug interaction considerations and hepatic/muscle/nerve safety signals and appropriate counseling concepts, but several extracted claims are not supported by the label (e.g., specific combination-related bleeding risk beyond anticoagulant interactions, atrial fibrillation-specific bleeding risk, and study details).
Category Scores
Monitoring Recommendations
75
Accurate Statements
Doxycycline can increase the risk of bleeding when combined with Lipitor, particularly in patients taking anticoagulant medications.
7.1
Doxycycline can cause liver damage.
5.3
Lipitor can cause liver damage.
5.3
Combining doxycycline and Lipitor may increase the risk of liver damage.
5.3
Lipitor can cause muscle damage, particularly in older adults.
5.3
Doxycycline can cause nervous system problems, including seizures.
5.3
Combining doxycycline and Lipitor may interact with other medications, including blood thinners, diabetes medications, and certain antibiotics.
7.1
Combining doxycycline and Lipitor may increase the risk of bleeding in patients taking anticoagulant medications.
7.1
Monitor liver function regularly while taking both medications.
5.11
Inform your doctor about any other medications you're taking, including over-the-counter medications and supplements.
17
Doxycycline and Lipitor can be taken together.
7.1
It's essential to be aware of potential side effects and take precautions to minimize the risk.
17
The potential side effects include increased risk of bleeding.
7.1
The potential side effects include liver damage.
5.3
The potential side effects include muscle damage.
5.3
The potential side effects include nervous system problems.
5.3
If you have a history of bleeding disorders, consult with your doctor before taking both medications.
17
If you're taking other medications, inform your doctor before taking both medications.
17
Unsupported Statements
Combining doxycycline with Lipitor may increase the risk of muscle damage.
No label evidence of a doxycycline–statin myopathy interaction.
Combining doxycycline and Lipitor may increase the risk of nervous system problems.
No label evidence of a neurotoxicity signal from the combination.
Combining doxycycline and Lipitor increased the risk of bleeding in patients with atrial fibrillation.
No label evidence tying atrial fibrillation specifically to increased bleeding with the combination.
The study investigating this had 100 patients.
Label does not reference a 100-patient study in the Safety/Clinical sections.
The risk of bleeding was significantly higher in patients taking both medications compared to those taking Lipitor alone.
No FDA-label statement confirming a head-to-head bleeding increase for this combination.
Monitor liver function regularly while taking both medications.
This is partially supported; while monitoring is advised, the statement as a blanket directive is not a standalone explicit claim in the label beyond specific sections.
Watch for signs of bleeding, such as bruising or bleeding gums.
Label does not explicitly list these signs in the stated sections; support is via anticoagulant interactions in 7.1 and counseling in 17.
Avoid taking other medications that may interact with doxycycline and Lipitor.
Label emphasizes management of interactions but not an absolute avoidance in all cases.
Doxycycline and Lipitor can be taken together.
Concomitant use is possible but requires monitoring; not a blanket endorsement without caveats.
The potential side effects include liver damage.
Partially supported; liver damage is a risk for both drugs, but the statement as a combined effect is not explicitly stated as such in the label.
Contradictions
Important Omissions
Pregnancy category/contraindication for doxycycline (pregnancy Category D) and pediatric safety (avoid in children <8 years) are not addressed in the claims but are material safety considerations in the label.
Importance:
High
Explicitly listing that statins (e.g., atorvastatin) have hepatotoxicity risk and require liver function monitoring in appropriate contexts; the claim set should reflect the label's explicit monitoring recommendations for hepatic risk with statins.
Importance:
Safety Assessment
Potential Patient Risk:
Moderate
There is potential hepatic risk and anticoagulant interaction risk with combination therapy; however, the claims asserting specific amplified bleeding with atrial fibrillation or a defined study outcome are not label-supported.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Overextension of bleeding risk and some non-labeled claims (e.g., atrial fibrillation-specific bleeding risk, a 100-patient study)
Suggested Improvement
Limit claims to label-supported interactions; avoid extrapolating to specific conditions (e.g., AF) or study details not present in the labeling; explicitly cite label sections for each claim; include pregnancy/pediatric contraindications and general counseling points from 17 and 5.11.